Precigen Actobio

Foundation date

2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.

We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.

Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.

Latest news

  • Mayne Pharma and Mithra announce TGA approval of Nextstellis® oral contraceptive

    23 hours ago

  • Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB

    23 hours ago

  • S-Biomedic announces topline results of a successful clinical study in acne

    Friday November 26th 2021

Jobs by Precigen Actobio